Epigenetic Biomarkers for Alzheimer's Disease

Identification of Epigenetic Biomarkers for Alzheimer's Disease in Blood Using Epigenome-wide Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04081285

Enrollment

250

Registered

2019-09-09

Start date

2019-09-01

Completion date

2024-11-30

Last updated

2025-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

Alzheimer's disease (AD) is a neurodegenerative disorder with no know cure. The pathogenesis of late onset AD (LOAD) is complex and multifactorial in nature, with multiple susceptibility genes and environmental factors at interplay. The objective of this study is to improve our understanding of the risk factors of LOAD by conducting an epigenome wide study within patients of LOAD contrasted against their cognitively normal siblings.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Sufficient Cantonese competency for cognitive test * Written informed consent given * Have at least one gender-matched cognitively normal sibling

Exclusion criteria

* Subjects who refuse blood taking procedure * Do not have a reliable family/caregiver informant (personal contact at least once a month)

Design outcomes

Primary

Measure	Time frame
DNA methylation	5 years
RNA-seq microbiome	5 years
Alzheimer's disease Assessment Scale-cognitive subscale (Adas-Cog)	5 years

Countries

Hong Kong

Outcome results